Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Adoptive T-cell therapies in the clinic.

Bioengineering & translational medicine·2026

Same author

Viral vector-based gene therapies in the clinic: An update.

Bioengineering & translational medicine·2026

Same author

Nanoparticle-boosted myeloid-derived suppressor cell therapy for immune reprogramming in multiple sclerosis.

Science advances·2025

Same author

Stem cell therapies in the clinic.

Bioengineering & translational medicine·2025

Same author

Integrating antigen capturing nanoparticles and type 1 conventional dendritic cell therapy for in situ cancer immunization.

Nature communications·2025

Same author

Antibody drug conjugates in the clinic.

Bioengineering & translational medicine·2024

Search research articles

Related Experiment Video

Updated: Jun 28, 2025

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

Genetically engineered cell-derived nanovesicles for cancer immunotherapy.

Shan He¹, Zongmin Zhao^1,2

¹Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, Chicago, IL 60612, USA. zhaozm@uic.edu.

|April 9, 2024

Summary

Genetically engineered extracellular vesicles (EVs) offer enhanced cancer immunotherapy by improving targeting and delivery of therapeutic agents. These modified EVs show promise for overcoming limitations of natural EVs in clinical applications.

More Related Videos

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jun 28, 2025

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Area of Science:

Oncology
Biotechnology
Nanomedicine

Background:

Immunotherapy has revolutionized cancer treatment, offering significant clinical benefits.
Extracellular vesicles (EVs) are natural nanocarriers with potential in cancer therapy due to their biocompatibility and low immunogenicity.
Natural EVs possess limitations including poor targeting, low drug loading, and unpredictable side effects.

Purpose of the Study:

To review the sources, isolation, and targeting of EVs.
To highlight genetic engineering strategies for enhancing EV-based cancer immunotherapy.
To discuss the clinical translation prospects and challenges of engineered EVs.

Main Methods:

Review of typical EV sources and isolation techniques.
Discussion of EV targeting strategies.
Analysis of genetic engineering approaches for modifying EVs.

Main Results:

Engineered EVs demonstrate improved delivery of immunomodulatory agents and antigen presentation.
Genetic modification enhances specific cancer targeting ability of EVs.
Modified EVs offer potential to overcome limitations of natural EVs.

Conclusions:

Genetically engineered EVs represent a promising platform for advanced cancer immunotherapy.
Further research is needed to address challenges in the clinical translation of engineered EVs.
EVs modified through genetic engineering deepen their role in cancer immunotherapy.